Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
The arrival of the monoclonal antibody (mAb) technology in the 1970s brought with it the hope of conquering cancers to the medical community. However, mAbs, on the whole, did not achieve the expected wonder in cancer therapy although they do have demonstrated successfulness in the treatment of a few...
Main Authors: | Zhaoying Fu, Jim Xiang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/8/2793 |
Similar Items
-
Aptamers as an approach to targeted cancer therapy
by: Fatemeh Mahmoudian, et al.
Published: (2024-03-01) -
Recent Progress and Opportunities for Nucleic Acid Aptamers
by: Jonghoe Byun
Published: (2021-02-01) -
Aptamers and antibodies: rivals or allies in cancer targeted therapy?
by: Lisa Agnello, et al.
Published: (2021-02-01) -
Aptamer selection and applications for breast cancer diagnostics and therapy
by: Mei Liu, et al.
Published: (2017-11-01) -
Aptamers and Cancer
by: Nasrin Yazdanpanahi, et al.
Published: (2016-04-01)